Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026)
Emergent BioSolutions (EBS) posted Cash from Investing Activities of -$52.3 million for Q2 2026, down 2079.17% on a QoQ basis from -$2.4 million in Q1 2026, and down 404.07% year-over-year from $17.2 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Cash from Investing Activities for 17 years, with the latest figure at -$52.3 million in Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 404.07% year-over-year to -$52.3 million in Q2 2026; TTM through Jun 2026 was -$62.0 million, a 128.53% decrease from a year earlier, with the FY2025 full-year figure at $69.4 million, down 44.57% from the prior year.
- Cash from Investing Activities was -$52.3 million for Q2 2026 at Emergent BioSolutions, down from -$2.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $257.7 million in Q2 2023, with the low at -$271.6 million in Q3 2022.
- Average Cash from Investing Activities over 5 years is -$1.6 million, with a median of -$7.7 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 902.8% in 2023, then tumbled 404.07% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$45.4 million in 2022, then soared by 74.89% to -$11.4 million in 2023, then jumped by 350.88% to $28.6 million in 2024, then plunged by 113.64% to -$3.9 million in 2025, then tumbled by 1241.03% to -$52.3 million in 2026.
- The last three Cash from Investing Activities figures came in at -$52.3 million (Q2 2026), -$2.4 million (Q1 2026), and -$3.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | -1.61 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | -424.26 Mn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | -49.35 Mn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | -1.66 Bn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | -52.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52.30 Mn |
| Mar 31, 2026 | -2.40 Mn |
| Dec 31, 2025 | -3.90 Mn |
| Sep 30, 2025 | -3.40 Mn |
| Jun 30, 2025 | 17.20 Mn |
| Mar 31, 2025 | 59.50 Mn |
| Dec 31, 2024 | 28.60 Mn |
| Sep 30, 2024 | 112.00 Mn |
| Jun 30, 2024 | -4.60 Mn |
| Mar 31, 2024 | -10.80 Mn |
| Dec 31, 2023 | -11.40 Mn |
| Sep 30, 2023 | -18.90 Mn |
| Jun 30, 2023 | 257.70 Mn |
| Mar 31, 2023 | -15.10 Mn |
| Dec 31, 2022 | -45.40 Mn |
| Sep 30, 2022 | -271.60 Mn |
| Jun 30, 2022 | -32.10 Mn |
| Mar 31, 2022 | -32.20 Mn |
| Dec 31, 2021 | -45.80 Mn |
| Sep 30, 2021 | -55.20 Mn |
API Access
Emergent BioSolutions Cash from Investing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-investing-activities&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-investing-activities", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-investing-activities&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();